The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Targeted Therapy of Advanced Non-Small Cell Lung Cancer

비소세포폐암 환자의 표적 치료

  • Yun-Gyoo Lee (Division of Hematology & Medical Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan Unversity School of Medicine) ;
  • Hyun-Il Gil (Division of Pulmonology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan Unversity School of Medicine) ;
  • Soo Jeong Kim (Department of Nuclear Medicine, Kangbuk Samsung Hospital, Sungkyunkwan Unversity School of Medicine) ;
  • Hyunjoo Lee (Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan Unversity School of Medicine) ;
  • Heerim Nam (Department of Radiation Oncology, Kangbuk Samsung Hospital, Sungkyunkwan Unversity School of Medicine) ;
  • Soo-Youn Ham (Department of Radiology, Kangbuk Samsung Hospital, Sungkyunkwan Unversity School of Medicine) ;
  • Du-Young Kang (Department of Thoracic & Cardiovascular surgery, Kangbuk Samsung Hospital, Sungkyunkwan Unversity School of Medicine)
  • 이윤규 (성균관대학교 의과대학 강북삼성병원 혈액종양내과) ;
  • 길현일 (성균관대학교 의과대학 강북삼성병원 호흡기내과) ;
  • 김수정 (성균관대학교 의과대학 강북삼성병원 핵의학과) ;
  • 이현주 (성균관대학교 의과대학 강북삼성병원 병리과) ;
  • 남희림 (성균관대학교 의과대학 강북삼성병원 방사선종양학과) ;
  • 함수연 (성균관대학교 의과대학 강북삼성병원 영상의학과) ;
  • 강두영 (성균관대학교 의과대학 강북삼성병원 심장혈관흉부외과)
  • Received : 2024.03.11
  • Accepted : 2024.04.01
  • Published : 2024.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

Lung cancer is the leading cause of cancer death in Republic of Korea. After their initial diagnosis, only 10-20% of patients with advanced non-small cell lung cancer (NSCLC) survive for 5 years of longer. Given enormous advances in therapeutics such as novel targeted therapies and immunotherapies, survival rates are improving for advanced patients with NSCLC; 5-year survival rates range from 15% to 50%, contingent upon the biomarker. Detection of the specific molecular alteration as biomarker is thus crucial for identifying subgroups of NSCLC that contain therpapeutically targetable oncogenic drivers. This review examines the process of diagnosing lung adenocarcinoma with dominant biomarkers in order to customize treatment with appropriate targeted therapy.

Keywords

References

  1. Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol 2022;17:362-387.
  2. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
  3. Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2023;34:339-357.
  4. Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2022;20:497-530.
  5. Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin 2017;67:93-99.
  6. Passaro A, Leighl N, Blackhall F, et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol 2022;33:466-487.
  7. Cho BC, Ahn MJ, Kang JH, et al. Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: results from LASER301. J Clin Oncol 2023;41:4208-4217.
  8. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378:113-125.
  9. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 2020;382:41-50.
  10. Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol 2021;39:3391-3402.
  11. Yang JC, Schuler M, Popat S, et al. Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases. J Thorac Oncol 2020;15:803-815.
  12. Selinger CI, Rogers TM, Russell PA, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2013;26:1545-1553.
  13. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-2177.
  14. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017;377:829-838.
  15. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol 2021;16:2091-2108.
  16. Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol 2020;31:1056-1064.
  17. Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 2020;383:2018-2029.
  18. Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer 2019;19:495-509.
  19. Lee JK, Kim TM, Koh Y, et al. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. Lung Cancer 2012;77:460-463.
  20. Rolfo C, Mack P, Scagliotti GV, et al. Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer. J Thorac Oncol 2021;16:1647-1662.
  21. Kang MJ, Jung KW, Bang SH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2020. Cancer Res Treat 2023;55:385-399.